Originally published by our sister publication Clinical Oncology News
The FDA approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved test.
Efficacy was evaluated in cohort 1 of MAGNITUDE, a randomized, double-blind, placebo-controlled trial enrolling 423 patients with